Alnylam (ALNY) PT Cut to $137 at Needham & Company; Long-Term Investors Should Buy Weakness
- Wall St set to open flat ahead of Easter break, eyes sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- Yen on intervention watch; Asia shares creep higher
- Dollar gains as inflation data looms; yen on intervention watch
- Piper Sandler: Stock rally likely to continue on rising recession risks
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan
October 6, 2016 7:39 AM EDTChardan Capital Markets analyst Madhu Kumar cut the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $77.00 (from $115.00) after the company announced the discontinuation of the development of revusiran, a RNAi drug
which was in phase III trials targeting transthyretin (TTR), for the treatment of TTR familial amyloid... More
Credit Suisse Cuts Alnylam (ALNY) PT to $50, Keeps 'Outperform'
October 6, 2016 7:23 AM EDTCredit Suisse analyst Alethia Young cut her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $50.00 (from $145.00) but maintained an Outperform after the company announced termination of revusiran.
Young commented, "Lowering TP to $50/sh due to concerns about broader implications to the... More
Alnylam (ALNY) PT Cut to $58 at Jefferies
October 6, 2016 6:47 AM EDTJefferies analyst Gena Wang lowered her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $58.00 (from $86.00) but maintained a Buy rating after the company announced termination of revusiran Ph3 due to mortality imbalance.
Wang commented, "Following recent discontinuation of ALN-AAT, ALNY announced termination of... More
Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback
October 6, 2016 6:44 AM EDTJefferies analyst Biren Amin reiterated his Buy rating and $43 price target on The Medicines Company (NASDAQ: MDCO) saying Alnylam Pharmaceuticals (NASDAQ: ALNY) set back has no read-through to the company's PCSK9 Program.
Amin commented, "ALNY... More
JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
October 6, 2016 6:41 AM EDTJPMorgan downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Neutral with a price target of $51.00 (from $83.00).
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.
... MoreBarclays Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight
October 6, 2016 6:41 AM EDTBarclays downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Equalweight with a price target of $50.00 (from $85.00).
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.
... MoreLeerink Partners Downgrades Alnylam Pharmaceuticals (ALNY) to Market Perform
October 6, 2016 6:39 AM EDTLeerink Partners downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Market Perform with a price target of $40.00 (from $107.00) after the company discontinued development of revusiran.
Analyst Michael Schmidt commented, "We are downgrading ALNY to Market Perform following today's news that the company has discontinued development of... More
BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam Failure
October 6, 2016 6:29 AM EDTBMO Capital upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Market Perform to Outperform with a price target of $48.00 (from $42.00), saying the company could benefit from Alnylam (NASDAQ: ALNY) discontinuation of the Revusiran program fter observing an imbalance of... More
Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect Patisiran
October 5, 2016 4:31 PM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This... More